Why examine NAD+ this closely?
The coenzyme is fascinating enough without making it answer every health question.
Before the Dr misleads anyone
NAD Dr is the name of this site, and I have no doctor’s qualifications. There is no practice here: no prescribing, selling, shipping or appointment booking. This is a close inspection of published NAD+ research, not medical advice.
The clinical ring of the name is exactly why the gap between a laboratory finding and a treatment claim interests me. I can examine the reputation of a molecule. I cannot examine a person, weigh a medical history or make a decision about treatment.
A coenzyme with no allegiance
NAD+ has a great cellular story: energy metabolism and cell-death pathways share it with repair and signaling enzymes. That scope is the reason the subject is compelling, and the reason a single replenishment slogan seems too small.
The melanoma experiment is the paper that most disrupted my expectation. Lowering NAD+ was part of attacking drug-resistant cancer cells in the lab and in mice. Beside the protective animal findings, it makes the coenzyme look less like a universal remedy and more like something whose consequences depend on where it is doing its work.
Curiosity survives an inconclusive verdict
The limited human clinical results leave my curiosity intact. A blood result can be robust and still leave a practical question open. The muscle trial is interesting because its effect is specific; the heart papers matter because their hoped-for consequences would matter.
An enlarged conclusion exhausts my patience faster than an inconclusive experiment. I would happily revise an opinion if a well-matched human trial joined the tissue result to a meaningful benefit. Until then, NAD+ is a subject worth following without an easy verdict.